Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of... Should measures be taken to reduce the risk of human parvovirus (B 19) infection by transfusion of blood components and clotting factor concentrates? Over the last several years, a seemingly endless array of infectious agents have occasionally been transmitted by blood components andor plasma derivatives. We had thought that human parvovirus (HPV, B19) was responsible only for a self-limited common childhoodexanthem, with a brief period of viremia. It is now known to be a virus that is capable of prolonged viremia,' latency with reactivation,2and possible reinfe~tion.~.~ proporA small tion of persons have serious, sometimes chronic, impaired production of erythroid and, sporadically, other bone marrow cells, as well as manifestations in other systems. In this issue of TRANSFUSION, Luban5makes clear that a great deal can be learned quickly about a virus and its pathogenesis by using the tools of molecular virology. She correctly points out how much more difficult is the definition of the type and variety of recipients for whom HPV infection has the potential to be clinically important. Definition of the number of serious acute and chronic HPV cases, particularly if they are sporadic, depends first upon the physician's being aware of the possible diagnosis. In addition, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?

Transfusion, Volume 34 (9) – Sep 1, 1994

Loading next page...
 
/lp/wiley/should-measures-be-taken-to-reduce-the-risk-of-human-parvovirus-b19-LU3qiAjI2F
Publisher
Wiley
Copyright
1994 AABB
ISSN
0041-1132
eISSN
1537-2995
D.O.I.
10.1046/j.1537-2995.1994.34994378271.x
Publisher site
See Article on Publisher Site

Abstract

Should measures be taken to reduce the risk of human parvovirus (B 19) infection by transfusion of blood components and clotting factor concentrates? Over the last several years, a seemingly endless array of infectious agents have occasionally been transmitted by blood components andor plasma derivatives. We had thought that human parvovirus (HPV, B19) was responsible only for a self-limited common childhoodexanthem, with a brief period of viremia. It is now known to be a virus that is capable of prolonged viremia,' latency with reactivation,2and possible reinfe~tion.~.~ proporA small tion of persons have serious, sometimes chronic, impaired production of erythroid and, sporadically, other bone marrow cells, as well as manifestations in other systems. In this issue of TRANSFUSION, Luban5makes clear that a great deal can be learned quickly about a virus and its pathogenesis by using the tools of molecular virology. She correctly points out how much more difficult is the definition of the type and variety of recipients for whom HPV infection has the potential to be clinically important. Definition of the number of serious acute and chronic HPV cases, particularly if they are sporadic, depends first upon the physician's being aware of the possible diagnosis. In addition,

Journal

TransfusionWiley

Published: Sep 1, 1994

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off